[Circulatory effects of a new specific beta adrenergic blocking agent, (o-(2-hydroxy-3-(tert. butylamino)-propoxyl)-benzonitrile, Kö 1366)].
D000433:1-Propanol / Q000008:administration & dosage / Q000494:pharmacology; D000284:Administration, Oral; D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002082:Butylamines / Q000008:administration & dosage / Q000494:pharmacology; D002302:Cardiac Output / Q000187:drug effects; D002306:Cardiac Volume / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007545:Isoproterenol; D008875:Middle Aged; D008954:Models, Biological; D009570:Nitriles / Q000008:administration & dosage / Q000494:pharmacology; D013610:Tachycardia / Q000139:chemically induced / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D002082:Butylamines; D009570:Nitriles; D000433:1-Propanol; D007545:Isoproterenol
Kreislaufwirkungen eines neuen spezifischen beta-Rezeptorenblockers (o-(2-Hydroxy-3-(tert. butylamino)-propoxy)-benzonitril, Kö 1366.